Focus Myocardial Infarction

Aposcience AG has identified APO-1 (APOSECTM), derived from the secretome of irradiated, apoptotic peripheral blood mononuclear cells (PBMCs) as superbly efficacious in reducing infarct size and maintaining left ventricular function in animal models of myocardial infarction (MI). These models tested MI with and without reperfusion, including one of ischemia and reperfusion.

These data are predictive for the prevention of adverse remodeling following revascularization of an acute MI. The target population are those over 700,000 patients worldwide who undergo reperfusion treatment for acute ST-elevation myocardial infarction. If APO-1 (APOSECTM) proves effective in clinical trials, the market potential is estimated at 1 – 2 billion Euros annually.

Latest News
Dec
12

Approval for clinical phase II study in DFU by Austrian health agency

[more]

Oct
10

US Patent Office issues Allowance for APOSEC Patent

[more]